Lastly, the findings from this study suggest that targeting MAGE-A10 with this TCR could be further optimized through improvements in T-cell manufacture, enhancement of the phenotypic composition of the T-cell product, or by targeting multiple antigens such as MAGE-A4 and A10 that are co-expressed in some tumors (as has been recently explored in lymphoma (36)). Here, MAGEA10 is linked to lymphoma.